News

Pharmaceutical and biotech product development consultancy Boyds has recruited Kathryn Bartley as Senior Clinical Research Associate.


The appointment follows last year’s acquisition of Blue Duck Consultancy which fueled the expansion of Boyds’ in-house clinical and medical affairs services offering.


Kathryn has over 18 years’ experience in the industry, primarily in study and site management and monitoring. Her work has covered a variety of therapy areas across all trial phases within both the commercial and academic sectors.

Cambridge, UK, 08 September 2020: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has significantly enhanced its global business development capabilities, with additional resources now committed to support key regions in the USA, Europe and Japan. 


 

Cambridge, UK, and Cambridge, MA, 08 September 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and XtalPi Inc., a leading algorithm-driven artificial intelligence (AI)-based pharmaceutical technology company, today announced they have entered into a drug discovery collaboration agreement. Financial details are not disclosed.

 


CAMBRIDGE, UK 09 September 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced a collaboration with leading, global high-performance analog technology company, Analog Devices, Inc. The companies will work together on the advancement and commercial scale-up of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips and accelerate the development of Evonetix’s first product, a DNA desktop writer. 


  • TTP will provide entrepreneurs with mentoring and tech consultancy, to accelerate product development and commercialisation

  • Agreement underlines TTP’s commitment to sharing knowledge and experience with innovative start-ups

  • TTP to deliver virtual seminar on 17 September as part of Start Codon and Cancer Research UK’s Entrepreneurial Training Scheme


 

Executive search consultancy, Horton International UK, has announced the appointment of Mark Johnson as Senior Partner of its Oxford-based Global Healthcare arm.

AMSBIO announce new additions and certifications for their market-leading range of clinical grade, chemically defined cryopreservation excipient solutions - STEM-CELLBANKER® and HSC-BANKER®.

Click here for the September issue of eNews. 


Cambridge, UK, 01 September 2020:  Mursla, a liquid biopsy company, has raised £410K from the UK Government’s Future Fund and existing investors. In addition, the organisation has secured a £40K COVID-19 grant from the Cambridgeshire Capital Grant Scheme.

The funding will enable Mursla to finalise its work on its novel exosome-based liquid biopsy platform, ExoPhenoTM, with the aim of demonstrating how the platform can detect cancer signatures in plasma from solid tumours via exosomes.

Pages